GeneDx Ebit from 2010 to 2025

WGSWW Stock   0.21  0.02  10.53%   
GeneDx Holdings EBIT yearly trend continues to be fairly stable with very little volatility. EBIT will likely drop to about -160.8 M in 2025. During the period from 2010 to 2025, GeneDx Holdings EBIT regression line of quarterly data had mean square error of 9410.9 T and geometric mean of  63,826,199. View All Fundamentals
 
EBIT  
First Reported
2010-12-31
Previous Quarter
-153.2 M
Current Value
-160.8 M
Quarterly Volatility
123.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GeneDx Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeneDx Holdings' main balance sheet or income statement drivers, such as Net Interest Income of 1.3 M, Interest Income of 3.1 M or Depreciation And Amortization of 31.3 M, as well as many indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or PTB Ratio of 0.52. GeneDx financial statements analysis is a perfect complement when working with GeneDx Holdings Valuation or Volatility modules.
  
Check out the analysis of GeneDx Holdings Correlation against competitors.

Latest GeneDx Holdings' Ebit Growth Pattern

Below is the plot of the Ebit of GeneDx Holdings Corp over the last few years. It is GeneDx Holdings' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeneDx Holdings' overall financial position and show how it may be relating to other accounts over time.
Ebit10 Years Trend
Slightly volatile
   Ebit   
       Timeline  

GeneDx Ebit Regression Statistics

Arithmetic Mean(108,186,558)
Geometric Mean63,826,199
Coefficient Of Variation(114.18)
Mean Deviation97,216,948
Median(30,413,000)
Standard Deviation123,531,608
Sample Variance15260.1T
Range430.8M
R-Value(0.65)
Mean Square Error9410.9T
R-Squared0.42
Significance0.01
Slope(16,903,569)
Total Sum of Squares228900.9T

GeneDx Ebit History

2025-160.8 M
2024-153.2 M
2023-170.2 M
2022-461.2 M
2021-242.6 M
2020-238.9 M

Other Fundumenentals of GeneDx Holdings Corp

About GeneDx Holdings Financial Statements

GeneDx Holdings investors use historical fundamental indicators, such as GeneDx Holdings' Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in GeneDx Holdings. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBIT-153.2 M-160.8 M
EBITDA-122.8 M-129 M
Ebt Per Ebit 0.97  0.72 
Ebit Per Revenue(0.93)(0.98)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.